[ad_1] TORONTO, May 15, 2025 /PRNewswire/ – MediPharm Labs Corp. (TSX: LABS) (“MediPharm” or the “Company“), a pharmaceutical company specialized in precision-based cannabinoids, today provided its shareholders with additional information about the six nominees for its […]

[ad_1] TORONTO, May 13, 2025 /PRNewswire/ – MediPharm Labs Corp. (TSX: LABS) (“MediPharm” or the “Company“), a pharmaceutical company specialized in precision-based cannabinoids, has filed its Management Information Circular (“MIC” or the “Circular“) and proxy materials […]

[ad_1] TORONTO, May 13, 2025 /PRNewswire/ – MediPharm Labs Corp. (TSX: LABS) (“MediPharm” or the “Company“), a pharmaceutical company specialized in precision-based cannabinoids, has filed its Management Information Circular (“MIC” or the “Circular“) and proxy materials […]

[ad_1] TORONTO, Nov. 11, 2024 /PRNewswire/ – MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release […]

[ad_1] Company Now Materially Debt Free with Over $13M in Cash TORONTO, Sept. 17, 2024 /PRNewswire/ – MediPharm Labs Corp. (“MediPharm” or the “Company”) (TSX: LABS), a specialized, research-driven pharmaceutical company focused on cannabis-based health products, […]